Porta C - Search Results

1

Pharmacotherapy for treating metastatic clear cell renal cell carcinoma.

Porta C, Chiellino S, Ferrari A, Mariucci S, Liguigli W. Porta C, et al. Expert Opin Pharmacother. 2017 Feb;18(2):205-216. doi: 10.1080/14656566.2017.1282462. Expert Opin Pharmacother. 2017. PMID: 28103447 Review.

2

Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study.

Porta C, Zimatore M, Imarisio I, Natalizi A, Sartore-Bianchi A, Danova M, Riccardi A. Porta C, et al. Cancer. 2004 May 15;100(10):2132-8. doi: 10.1002/cncr.20226. Cancer. 2004. PMID: 15139055 Free article. Clinical Trial.

3

Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients.

Sartore-Bianchi A, Soriani A, Mattioni R, Vaglio A, Buzio C, Porta C. Sartore-Bianchi A, et al. Among authors: porta c. Oncol Rep. 2004 Oct;12(4):855-9. Oncol Rep. 2004. PMID: 15375512

4

Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.

Porta C. Porta C. Expert Rev Anticancer Ther. 2006 Jan;6(1):141-52. doi: 10.1586/14737140.6.1.141. Expert Rev Anticancer Ther. 2006. PMID: 16375651 Review.

5

Sigmoid colon metastasis from sarcomatoid renal cell carcinoma.

Invernizzi R, Bencardino K, Porta C, Vercelli A, Viglio A, Manzoni M, Sagrada P, Danova M. Invernizzi R, et al. Among authors: porta c. Tumori. 2006 May-Jun;92(3):246-8. doi: 10.1177/030089160609200312. Tumori. 2006. PMID: 16869245

6

Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells.

Porta C, Bonomi L, Lillaz B, Paglino C, Rovati B, Imarisio I, Morbini P, Villa C, Danova M, Mensi M, Rovereto B. Porta C, et al. Anticancer Res. 2007 Jan-Feb;27(1A):165-73. Anticancer Res. 2007. PMID: 17352228 Free article.

7

Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents.

Porta C, Paglino C, Imarisio I, Bonomi L. Porta C, et al. ScientificWorldJournal. 2007 Apr 9;7:837-49. doi: 10.1100/tsw.2007.154. ScientificWorldJournal. 2007. PMID: 17619768 Free PMC article. Review.

8

Tolerability of first-line therapy for metastatic renal cell carcinoma.

Porta C, Szczylik C. Porta C, et al. Cancer Treat Rev. 2009 May;35(3):297-307. doi: 10.1016/j.ctrv.2008.12.003. Epub 2009 Feb 26. Cancer Treat Rev. 2009. PMID: 19249157 Review.

9

Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.

Passalacqua R, Buzio C, Buti S, Porta C, Labianca R, Pezzuolo D, Camisa R, Sabbatini R, Benecchi L, Messina C, Cengarle R, Vaglio A, Dalla Chiesa M, Tomasello G, Caminiti C. Passalacqua R, et al. Among authors: porta c. Cancer Immunol Immunother. 2010 Apr;59(4):553-61. doi: 10.1007/s00262-009-0773-9. Epub 2009 Sep 25. Cancer Immunol Immunother. 2010. PMID: 19779715 Free PMC article. Clinical Trial.

10

Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma.

Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P. Porta C, et al. Cancer Treat Rev. 2010 Feb;36(1):16-23. doi: 10.1016/j.ctrv.2009.09.001. Epub 2009 Oct 9. Cancer Treat Rev. 2010. PMID: 19819078 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

953 results

Search Page